Trial Profile
E2022 Patch Formulation Multiple Dose Phase I Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2012
Price :
$35
*
At a glance
- Drugs Donepezil (Primary) ; Donepezil
- Indications Alzheimer's disease; Aphasia; Attention deficit and disruptive behaviour disorders; Dementia; Migraine; Mild cognitive impairment; Vascular dementia
- Focus Pharmacokinetics
- 30 May 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 30 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Oct 2011 New trial record